Literature DB >> 32408057

Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study.

Marina Buciuc1, Jennifer L Whitwell2, Nirubol Tosakulwong3, Stephen D Weigand3, Melissa E Murray4, Bradley F Boeve1, David S Knopman1, Joseph E Parisi5, Ronald C Petersen1, Dennis W Dickson4, Keith A Josephs6.   

Abstract

Association between the transactive response DNA-binding protein of 43 kDa (TDP-43), its newly described types (type α/type β), and resilience to Alzheimer's disease neuropathological change (ADNC) defined as preservation of normal cognitive functioning despite advanced ADNC has been evaluated in this case-control study of 63 older adults. Twenty-one resilient to ADNC individuals were matched 1:2 to nonresilient (Alzheimer's dementia) using propensity scores, accounting for age at death, neuritic plaque density, and neurofibrillary tangle stage. Resilient and matched nonresilient participants were similar in terms of gender, apolipoprotein E ε4 carriership, education, occupation, AD, and other pathologies. Resilient participants had lower frequency of TDP-43 co-pathology compared to nonresilient (19% vs. 62%, p = 0.002). Among TDP-43-positive cases, TDP-43 type α inclusions were absent in resilient to ADNC participants and were dominant in matched nonresilient cases (65%, p = 0.03). TDP-43 and TDP-43 types appear to be one of the key pathological determinants of loss of cognitive resilience to ADNC and hence are important in the understanding of the clinical expression of ADNC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Cognition; Normal aging; Resilience; TDP-43; TDP-43 types

Mesh:

Substances:

Year:  2020        PMID: 32408057      PMCID: PMC7682814          DOI: 10.1016/j.neurobiolaging.2020.04.001

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  30 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  TDP-43 is a key player in the clinical features associated with Alzheimer's disease.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; Nirubol Tosakulwong; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; David S Knopman; Bradley F Boeve; Robert J Ivnik; Glenn E Smith; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-03-23       Impact factor: 17.088

3.  Neuropathology of older persons without cognitive impairment from two community-based studies.

Authors:  D A Bennett; J A Schneider; Z Arvanitakis; J F Kelly; N T Aggarwal; R C Shah; R S Wilson
Journal:  Neurology       Date:  2006-06-27       Impact factor: 9.910

4.  Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.

Authors:  John L Robinson; Edward B Lee; Sharon X Xie; Lior Rennert; EunRan Suh; Colin Bredenberg; Carrie Caswell; Vivianna M Van Deerlin; Ning Yan; Ahmed Yousef; Howard I Hurtig; Andrew Siderowf; Murray Grossman; Corey T McMillan; Bruce Miller; John E Duda; David J Irwin; David Wolk; Lauren Elman; Leo McCluskey; Alice Chen-Plotkin; Daniel Weintraub; Steven E Arnold; Johannes Brettschneider; Virginia M-Y Lee; John Q Trojanowski
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

Review 5.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

6.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

7.  Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.

Authors:  K A Josephs; J L Whitwell; D S Knopman; W T Hu; D A Stroh; M Baker; R Rademakers; B F Boeve; J E Parisi; G E Smith; R J Ivnik; R C Petersen; C R Jack; D W Dickson
Journal:  Neurology       Date:  2008-04-09       Impact factor: 9.910

Review 8.  Resistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies.

Authors:  Eider M Arenaza-Urquijo; Prashanthi Vemuri
Journal:  Neurology       Date:  2018-03-28       Impact factor: 9.910

9.  Consensus recommendations on pathologic changes in the hippocampus: a postmortem multicenter inter-rater study.

Authors:  Tuomas Rauramaa; Maria Pikkarainen; Elisabet Englund; Paul G Ince; Kurt Jellinger; Anders Paetau; Irina Alafuzoff
Journal:  J Neuropathol Exp Neurol       Date:  2013-06       Impact factor: 3.685

10.  Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort.

Authors:  Caitlin S Latimer; Bridget T Burke; Nicole F Liachko; Heather N Currey; Mitchell D Kilgore; Laura E Gibbons; Jonathan Henriksen; Martin Darvas; Kimiko Domoto-Reilly; Suman Jayadev; Tom J Grabowski; Paul K Crane; Eric B Larson; Brian C Kraemer; Thomas D Bird; C Dirk Keene
Journal:  Acta Neuropathol Commun       Date:  2019-06-07       Impact factor: 7.578

View more
  4 in total

1.  Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia.

Authors:  Arenn F Carlos; Nirubol Tosakulwong; Stephen D Weigand; Bradley F Boeve; David S Knopman; Ronald C Petersen; Aivi Nguyen; R Ross Reichard; Melissa E Murray; Dennis W Dickson; Keith A Josephs
Journal:  Acta Neuropathol       Date:  2022-05-10       Impact factor: 15.887

2.  Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.

Authors:  Keith A Josephs; Stephen D Weigand; Jennifer L Whitwell
Journal:  Neurology       Date:  2022-03-21       Impact factor: 11.800

3.  TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death.

Authors:  Marina Buciuc; Nirubol Tosakulwong; Mary M Machulda; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; R Ross Reichard; Joseph E Parisi; Dennis W Dickson; Bradley F Boeve; David S Knopman; Ronald C Petersen; Keith A Josephs
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 4.  The Future of Seed Amplification Assays and Clinical Trials.

Authors:  Thomas Coysh; Simon Mead
Journal:  Front Aging Neurosci       Date:  2022-06-22       Impact factor: 5.702

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.